January 14, 2021 5:15pm

Numbers based facts speak better then opinion as I see answers in numbers

Pre-open indication: 6 HITs and 0 MISS

Are we here to make money or see it erode as some sessions devolve? 

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting!

The Dow closed DOWN -68.95 points (-0.22); the S&P closed DOWN -14.30 points (-0.38%) while the Nasdaq closed DOWN -16.31 points (-0.12%)

 

Henry’omics:

Indexes traded along the flatline on Thursday, as the unveiling of fiscal aid/stimulus package of $1.9 trillion will be presented that will include a boost to the recent $600 direct payments, an extension of increased unemployment insurance and support for state and local governments and then weighed against “slowpoke” positive vaccine inoculations in some states.

Well said, "At a certain point tough jobs numbers like we saw (Thursday) can serve as the tinder for those calling for a correction, but the market’s view seems to be that the light at the end of the tunnel remains in sight, despite a plodding vaccination rollout," said Mike Loewengart, managing director of investment strategy at E-Trade.

Further, a bleaker-than-expected jobs report translates into a greater likelihood for a full-throated stimulus package, which perversely acts as a tailwind for the market." <thestreet.com>

 

Data Docket: First-time claims for unemployment insurance jumped to 965,000 last week, higher than an estimate of 800,000 new claims, according to economists.

 

Sentiment and COVID-19 infections:

  • Federal Reserve chairman Powell sees no interest rate hikes on the horizon as long as inflation stays low
  • Trial data (published on Wednesday) showed that Johnson & Johnson’s (JNJ) one-dose coronavirus vaccine is safe and generates a promising immune response.

Infection cases <Million>: never to forget …

  • Thursday 23.10 M cases,
  • Thursday’s death rate totaled 385,503 <Johns Hopkins University>

 

This a.m.’s post, “sector resembles a dine and dash scenario. Markets seem to have shrugged off Washington’s political conflict, will it continue?” … https://www.regmedinvestors.com/articles/11721

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Thursday opened positive at 22/10 and 3 flats, stayed positive at the mid-day to 23/9 and 3 flats, closing positive at 27/7 and 1 acquired;
  • Wednesday opened positive at 18/15 and 2 flats, slipped negative at the mid-day to 14/18 and 3 flats, closing negative at 10/21, 3 flats and 1 acquired;
  • Tuesday opened positive at 27/7 and 1 flat, stayed positive at the mid-day at 20/14 and 1 acquired, closing positive at 21/13 and 1 acquired;
  • Monday opened negative at 20/14 and 1 flat, stayed negative at the mid-day at 12/20 and 3 flats, closing negative at 13/20, 1 flat and 1 acquired;

 

Pre-open indication:

  • 6 HITs < Maintaining SELL: Biostage (BSTG -$0.02 with 295 shares traded; BUYs: Applied Genetic Technologies (AGTC +$0.12), bluebird bio (BLUE +$2.36), Precigen (PGEN +$0.19), Ultragenyx (RARE +$5.16), Verastem (VSTM +$0.05)> 0 MISS

 

Key metrics:

  • Sector volume was LOW with 10 of the 27-upside having higher than the 3-month average volume with the increased volume of 1 of 7-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 27-upside were +0.13% (QURE) to +9.59% (NTLA) while the 7-downside ranges from -1.69% (BSTG) to -5% (RENE.L);

 

There are clear winners — and losers — heading into the first month of 2021.

52-week high

  • IBB reached an all-time high of 161.23, CRISPR Therapeutics (CRSP) reached an all-time high of $212.50, Fate Therapeutics (FATE) reached an all-time high of $120.00

Hammered in today’s market:

  • ReNeuron (RENE.L), Alnylam Pharmaceuticals (ALNY), BioLife Solutions (BLFS), AxoGen (AXGN), Mesoblast (MESO) to name 5 of the 7 declining of the 35 covered

Jumping with share pricing momentum:

  • CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Fate Therapeutics (FATE), Ultragenyx (RARE), Editas Medicine (EDIT) to name 5 of the 27 inclining of the 35 covered

 

Thursday’s (10 of 27) incliners:

  • CRISPR Therapeutics (CRSP +$16.20 after Wednesday’s +$3.50, Tuesday’s +$1.46 and Monday’s -$4.94)
  • Intellia Therapeutics (NTLA +$7.29 after Wednesday’s +$0.32, Tuesday’s +$2.91 and Monday’s -$5.58);
  • Ultragenyx (RARE +$5.16 after Wednesday’s -$2.93, Tuesday’s -$4.10 and Monday’s -$8.85);
  • Fate Therapeutics (FATE +$4.11 after Wednesday’s +$1.24);
  • Editas Medicine (EDIT +$2.62 after Wednesday’s -$1.70, Tuesday’s -$1.94 and Monday’s -$13.64);
  • Regenxbio (RGNX +$2.52 after Wednesday’s -$1.31, Tuesday’s +$0.61 and Monday’s +$1.17);
  • bluebird bio (BLUE +$2.36 after Wednesday’s -$2.84, Tuesday’s +1.93 and Monday’s +$1.86);
  • Ionis Pharmaceuticals (IONS +$1.70 after Wednesday’s +$0.50, Tuesday’s -$2.95 and Monday’s +$1.06);
  • Cellectis SA (CLLS +$1.68 after Wednesday’s +$1.39);

Thursday’s (7 of 7) decliners:

  • ReNeuron (RENE.L -$6.00);
  • Alnylam Pharmaceuticals (ALNY -$5.86 after Wednesday’s+$5.28, Tuesday’s +$9.02 and Monday’s +$9.97);
  • BioLife Solutions (BLFS -$0.54 after Wednesday’s +$2.36 and Tuesday’s -$0.34);
  • AxoGen (AXGN -$0.53);
  • Mesoblast (MESO -$0.31);
  • Solid Biosciences (SLDB -$0.20);
  • Biostage (BSTG -$0.02);

Closing flat 1 -Stemline Therapeutics (STML – acquired)

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed up +2.43% and XBI closed up +3.27%
  • Wednesday, the IBB closed down -0.21% and XBI closed down -0.52%
  • Tuesday, the IBB closed up +0.25% and XBI closed up +0.87%
  • Monday, the IBB closed down -0.16% and XBI closed down -0.99%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +1.04 points or +4.68% at 23.25
  • Wednesday was down -1.12 points or -4.80% at 22.21
  • Tuesday was down -0.75 points or -3.11% at 23.33
  • Monday was up +2.52 points or +11.69% at 24.08

Upside volume:

  • Thursday: 10 out of the 27-upside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 10-upside had higher than the 3-month average volume;
  • Tuesday: 8 out of the 21-upside had higher than the 3-month average volume;
  • Monday: 5 out of the 13-upside had higher than the 3-month average volume;

Downside volume:

  • Thursday: 1 out of the 7-downside had higher than the 3-month average volume;
  • Wednesday: 5 out of the 21-downside had higher than the 3-month average volume;
  • Tuesday: 5 out of the 13-downside had higher than the 3-month average volume;
  • Monday: 10 out of the 20-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Thursday’s percentage (%) of the 27-upside were +0.13% (QURE) to +9.59% (NTLA) while the 7-downside ranges from -1.69% (BSTG) to -5% (RENE.L);
  • Wednesday’s percentage (%) of the 10-upside were +0.42% (NTLA) to +6.29% (GBT) while the 21-downside ranges from -0.82% (BLCM) to -5.43% (BLUE);
  • Tuesday’s percentage (%) of the 21-upside were +0.04% (FATE) to +12.25% RENE.L() while the 13-downside ranges from -0.77% (MDXG) to -10.18% (MESO);
  • Monday’s percentage (%) of the 13-upside were +0.17% (SAGE) to +31.64% (MESO) while the 20-downside ranges from -0.62% (CLBS) to -15.06% (EDIT);

 

January, the 1st month of Q1 …

Thursday closed positive with 27 advancers, 7 decliners and 1 flat

Wednesday closed positive with 10 advancers, 21 decliners and 4 flats

Tuesday closed positive with 21 advancers, 13 decliners and 1 flat

Monday (1/11) closed negative with 13 advancers, 20 decliners and 2 flats

Friday closed negative with 16 advancers, 18 decliners and 1 flat

Thursday closed positive with 31 advancers, 2 decliners and 2 flats

Wednesday closed positive with 22 advancers, 12 decliners and 1 flat

Tuesday closed positive with 19 advancers, 14 decliners and 2 flats

Monday (1/4) closed positive with 26 advancers, 7 decliners and 2 flats

 

The Bottom Line: What’s changed, there is STILL a short-term tone shift in the market. I keep reiterating, “Sector volatility remains fluid … as I had stated, “you should take some profits even if some money is left on the table – safety is cash in your pocket of portfolio!”

It’s nice to be “RIGHT” again … in selling the highs and buying the dips!

Never forget, the “hungry” Pac-man algorithms satiate as the sector soars – get there FIRST!

Forewarned … Earnings LPS (los-per-share) season is coming quickly – my advice, trim and skim!!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.